IPO Watch · November 6, 2026
Coverage Period November 2–6, 2026 — Issuers, Founders, Backers, Bookrunners & the State of the Listing Pipeline
Anthropic, Wonder Group and OPay Lead This Week’s IPO Developments
The week of November 2–6, 2026 produced three distinct signals about the state of the public-market window. Anthropic filed an amended prospectus on November 2 with additional financial information — including third-quarter 2026 revenue reported at approximately $17 billion — while Reuters reported on November 5 that prospective investors were questioning valuation expectations and the timing of the planned roadshow. Wonder Group confidentially filed for a US IPO on November 5. And OPay terminated its offering on November 2 after pricing at $19 per share in a roughly $304 million deal, citing a regulatory inquiry.
The through-line: the window is open, but it is not permissive. A company can file, amend, price — and still not trade. A company with $17 billion of quarterly revenue can still face investor pushback on valuation. A company can reach a reported $9 billion pre-money private valuation and choose a confidential filing rather than a public one. This is a market that will accept issuers, but on terms it sets rather than terms the issuer proposes.
Editorial Note: This edition distinguishes confidential filings, public filings, amendments, pricing, withdrawals, terminations and completed listings throughout. Reported valuation expectations are not offering valuations; the Anthropic IPO price range and share count remain subject to the eventual prospectus, and the reported $1.5 trillion figure is an expectation attributed to sources, not a confirmed valuation. Private funding-round valuations are not IPO valuations. Non-technology issuers are included only where they illustrate a market development.
The Biggest IPO Story
Amended Prospectus Filed November 2 as Investors Question Valuation and Roadshow Timing
Public S-1 on file; amended prospectus filed November 2, 2026 · Proposed ticker ANT · Nasdaq Global Select Market.
The filing: Anthropic has a public S-1 on file and filed an amended prospectus on November 2, 2026, with additional financial information. The company intends to list on the Nasdaq Global Select Market under the proposed ticker ANT. No price range, share count or offering size has been set in the materials reviewed.
Disclosed financial context: Third-quarter 2026 revenue was reported at approximately $17 billion. The company has disclosed substantial AI computing and infrastructure commitments — a disclosure that matters as much as the revenue figure, because it tells prospective investors what proportion of future revenue is already committed to compute costs.
The syndicate: Goldman Sachs is the lead underwriter. The syndicate includes Morgan Stanley, J.P. Morgan, Citigroup, Barclays, Wells Fargo, Bank of America, Deutsche Bank, RBC Capital Markets and UBS, among others. Retail distribution participants identified in the filing include Charles Schwab, Fidelity, Robinhood, SoFi and E*TRADE.
The development: Reuters reported on November 5 that prospective investors were questioning the company’s valuation expectations and the timing of the planned roadshow. The reported $1.5 trillion valuation discussion is an expectation attributed to sources, not a confirmed offering valuation. No price range has been filed.
Why it matters: The nine-bank syndicate plus five retail distribution participants describes an offering engineered for maximum demand breadth — institutional coverage across every major US bank, plus direct retail access through the platforms where individual investors actually trade. That structure is not used for a routine technology IPO. It is used when the issuer and its bankers expect the book to be contested, and when the pricing decision will be made on a very wide range of investor opinion. The investor pushback reported on November 5 is precisely what such a syndicate exists to absorb: it is the process working, not the process failing. Whether it works will be determined by whether a price range gets filed and a roadshow gets scheduled — neither of which has happened yet.
What is not established: Offering valuation, price range, share count, offering size, roadshow dates and expected listing date. All remain subject to the eventual prospectus.
New IPO Entrants
Marc Lore Files Confidentially for a US IPO After a $650 Million Round at a Reported $9 Billion Pre-Money Valuation
Confidential filing announced November 5, 2026 · No price range, offering size, share count or public syndicate disclosed.
The filing: Wonder Group has confidentially filed for a US IPO. No price range, offering size, share count or public underwriting syndicate has been disclosed.
The people: Marc Lore is founder and CEO. Investors named in coverage include Accel, GV, AllianceBernstein and ARK Invest. Zipline is the company’s delivery technology partner.
The business: Wonder combines food halls, restaurant brands, delivery operations and technology. It has expanded through acquisitions including Grubhub and Blue Apron. It plans to introduce drone deliveries in Texas through its Zipline partnership. Its July 2026 funding round raised $650 million at a reported $9 billion pre-money valuation.
Why it matters: A confidential filing is a deliberate choice, not a shortcut. It lets an issuer test the SEC review process and gauge investor appetite without publishing its financials or committing to a timetable. For a company built through acquisition — Grubhub, Blue Apron and an operating restaurant footprint — the confidential route is particularly useful: it allows the issuer to work through accounting and segment-reporting questions with the SEC before those numbers become public and become part of the valuation debate. The reported $9 billion pre-money valuation is a private funding-round figure and must not be read as an IPO valuation; the two are set by different markets under different conditions.
Formerly NodThera, the Biotech Seeks $181 Million at $11–$13 Per Share for Its NLRP3 Inhibitor Programme
Amended S-1 filed November 5, 2026 · Proposed offering terms added.
The filing: Rezera Inc., formerly NodThera, filed an amended S-1 on November 5 with proposed offering terms: 16.7 million shares at an indicative $11–$13 per share, seeking approximately $181 million.
The people and banks: Geoffrey McDonough is CEO. Jefferies, TD Cowen and Cantor are joint bookrunners; Wedbush PacGrow is lead manager. GSK is the counterparty under a right-of-first-negotiation and clinical advisory agreement.
Use of proceeds: Development of the company’s NLRP3 inhibitor and progression toward Phase 3 clinical trials.
Why it matters: Rezera is the week’s clearest example of a functioning IPO process. It has moved from filing to amended terms, with a defined price range, share count, syndicate and stated use of proceeds — the sequence every issuer needs to complete before a roadshow. The GSK right-of-first-negotiation is a material disclosure for biotech investors: it tells them a large pharmaceutical counterparty has an interest in the asset, which affects both the strategic optionality and the eventual commercial terms. The inclusion of a specialist bank — Wedbush PacGrow, a healthcare-focused franchise — alongside generalist bookrunners is standard for clinical-stage biotech and reflects the specialist investor base such offerings target.
IPO Withdrawal and Market Setbacks
A $304 Million Offering at $19 Per Share Is Withdrawn Before Trading, Citing a Regulatory Inquiry
Terminated November 2, 2026 — after pricing, before trading.
What happened: OPay had priced its offering at $19 per share in a proposed offering of approximately $304 million. The company terminated the IPO before its shares began trading. OPay cited a regulatory inquiry involving a jurisdiction it described as immaterial to its business.
The people and banks: SoftBank is a prominent investor. Reported investors include IDG Capital, HSG, GSR Ventures and Source Code Capital. Citi, Deutsche Bank, Standard Bank and CICC were joint bookrunners.
Why it matters: This is the most instructive transaction of the week, and the least reported relative to its significance. A priced IPO is the point at which the issuer, the bankers and the investors have all agreed on terms. Terminating after pricing is rare enough that it deserves attention: it means a material development emerged between the pricing decision and the first trade. The company’s own framing — a regulatory inquiry in a jurisdiction it characterizes as immaterial — is an assertion about materiality, not a settled finding. Investors and counterparties will want to understand what the inquiry concerns, which regulator is involved and whether other jurisdictions could follow. The joint bookrunner list, spanning US, European, African and Chinese institutions, reflects OPay’s positioning as an emerging-markets fintech, and it also means the withdrawal was visible to four separate underwriting desks simultaneously.
An Industrials Issuer Pulls Its Filing as Market Conditions Are Reassessed
Withdrawn November 4, 2026 · Sector: industrials / consultancy.
What happened: DT House Limited, an industrials and consultancy company, withdrew its IPO on November 4. ATISUS was the listed bookrunner.
Why it matters: A withdrawal at this stage, from a company outside the technology sector, is a useful control on the week’s narrative. The IPO window is not a single market — it is a set of sector-specific windows that open and close on different schedules. OPay and DT House both withdrew in the same week that Anthropic amended a prospectus and Rezera added priced terms. The pattern is not a closed window; it is a window that is open for some issuers and shut for others, with the deciding factors being sector appetite, size and any unresolved disclosure issues.
The Players Behind the IPOs
The underwriting syndicates are the clearest read on deal expectations. Anthropic’s nine-bank syndicate, led by Goldman Sachs, is built for a large, contested, institutionally broad offering. Rezera’s four-bank syndicate — Jefferies, TD Cowen, Cantor and Wedbush PacGrow — is built for a specialist healthcare investor base. OPay’s four-bank syndicate — Citi, Deutsche Bank, Standard Bank and CICC — is built for an emerging-markets fintech with cross-border distribution needs. None of these is a generic arrangement; each reflects the specific investor profile the issuer needs to reach.
Retail distribution is now part of the institutional design. Anthropic’s filing identifies Charles Schwab, Fidelity, Robinhood, SoFi and E*TRADE as retail distribution participants. That is a structural choice with consequences: it broadens the demand base beyond institutions, it can support pricing in a contested book, and it increases the issuer’s post-listing shareholder-management burden. For a company of Anthropic’s profile, the inclusion of direct retail access signals that the issuer expects individual-investor demand to be material to the outcome.
Private backers are the quiet variable in every filing. Wonder’s investor list — Accel, GV, AllianceBernstein, ARK Invest — and OPay’s — SoftBank, IDG Capital, HSG, GSR Ventures, Source Code Capital — describe the shareholders whose positions will be marked to a public price for the first time. Their willingness to support a listing, their lock-up terms and their post-IPO selling intentions are material to the aftermarket, even though they rarely appear in the headline coverage. Institutional backers such as AllianceBernstein and ARK Invest in particular are public-market investors by trade; their presence in a private round is a signal about how the company expects to be valued once listed.
The sponsor matters as much as the structure in SPAC filings. Michael Klein and the Churchill Capital platform are behind Churchill Capital Corp XIV, which filed an S-1 on November 4 for approximately $300 million. A sponsor’s track record is the primary diligence input for SPAC investors, because the structure offers no operating business to evaluate. We do not speculate about a future target unless one is formally disclosed.
The IPO Pipeline
| Issuer | Status | Detail |
|---|---|---|
| Anthropic, PBC | Public S-1; amended prospectus November 2 | Nasdaq Global Select · ticker ANT · Q3 2026 revenue ~$17B · valuation expectations questioned (Reuters, November 5) |
| Wonder Group | Confidential filing announced November 5 | Founder/CEO Marc Lore · July 2026 round $650M at reported $9B pre-money |
| Rezera Inc. | Amended S-1 November 5 | ~$181M · 16.7M shares · $11–$13 indicative range · Jefferies, TD Cowen, Cantor, Wedbush PacGrow |
| Churchill Capital Corp XIV | S-1 filed November 4 | SPAC · ~$300M · Michael Klein / Churchill Capital platform |
| OPay | Terminated November 2 | Priced at $19 · ~$304M · Citi, Deutsche Bank, Standard Bank, CICC |
| DT House Limited | Withdrawn November 4 | Industrials / consultancy · bookrunner ATISUS |
| Guitar Group Ltd | F-1 filed November 5 | Proposed US listing |
| Kartoon Studios Acquisition Corp | Filed November 5 | SPAC · $300M proposed offering |
| American Ventures Acquisition I | Amended | SPAC offering reduced to $75M |
Business, founders or sponsors, underwriters and exchange are identified only where supported by filings. Smaller issuers are listed for monitoring and are not given equal editorial weight.
What These Moves Signal
Valuation discipline is being set by investors, not issuers. The Anthropic situation is the clearest illustration: a company with $17 billion of quarterly revenue and a nine-bank syndicate is still facing reported investor questions about valuation. That is not a sign of weakness in the issuer. It is a sign that public-market investors have a view on AI infrastructure economics — including the multi-year compute commitments Anthropic has disclosed — and are prepared to apply it before a price range is set.
Regulatory risk has moved from a disclosure item to an execution risk. OPay is the week’s most important lesson. A regulatory inquiry in a jurisdiction the company describes as immaterial to its business was sufficient to terminate a priced $304 million offering. Investors will now price in the possibility of a similar outcome at any emerging-markets fintech listing, and underwriters will need to add regulatory contingency to their timetables in a way that was less common when IPO windows were wider.
Confidential filings are becoming the default entry point. Wonder chose a confidential filing at a reported $9 billion private valuation. That choice lets an issuer work through accounting and disclosure issues privately before the numbers become part of the public valuation debate. For companies assembled through acquisition — where segment reporting and purchase accounting are genuinely complicated — the confidential route is not a sign of hesitation. It is a sign of preparation.
The biotech window is functioning independently of the technology window. Rezera moved from filing to priced terms within the same week that OPay terminated and DT House withdrew. That divergence is what a sector-specific market looks like. Issuers, investors and bankers should stop treating “the IPO market” as a single environment and start treating it as a set of windows that open on different schedules.
What to Watch Next
Confirmed developments
- Anthropic — amended prospectus filed November 2; public S-1 on file; Nasdaq Global Select; ticker ANT proposed.
- Wonder Group — confidential filing announced November 5.
- Rezera Inc. — amended S-1 with priced terms filed November 5.
- OPay — IPO terminated November 2 after pricing at $19.
- DT House Limited — IPO withdrawn November 4.
- Churchill Capital Corp XIV — S-1 filed November 4 for ~$300M SPAC.
To monitor — not yet confirmed
- Anthropic price range, share count and roadshow dates — none has been filed. The reported $1.5 trillion valuation figure remains an expectation, not a confirmed offering valuation.
- Whether Anthropic’s offering proceeds on its current timetable — reported investor pushback on valuation and timing is a signal to watch, not a decision.
- Wonder’s public S-1 — a confidential filing becomes public when the issuer proceeds; the financials will be the first hard data on the combined Grubhub and Blue Apron business.
- Rezera’s pricing and listing date — the transition from indicative range to final terms is the next milestone.
- Details of the OPay regulatory inquiry — which regulator, which jurisdiction, what the inquiry concerns, and whether other jurisdictions follow.
- Whether OPay refiles — and on what terms.
- Churchill Capital Corp XIV’s target — we do not speculate about a future target unless one is formally disclosed.
- Guitar Group and Kartoon Studios Acquisition Corp — monitoring of new F-1 and SPAC filings.
- Additional withdrawals — the rate of withdrawal is the most reliable indicator of whether the window is narrowing.
The week’s most important IPO development was not a filing. It was a termination.
OPay had priced. Its bankers — Citi, Deutsche Bank, Standard Bank and CICC — had run the book. Its investors, including SoftBank, had agreed to terms. And then a regulatory inquiry in a jurisdiction the company describes as immaterial to its business was sufficient to end the offering before a single share traded. That outcome should be read as the definitive statement of the week: the IPO window is open, but the price of entering it now includes a regulatory contingency that did not exist in the recent past. Issuers and their advisers who treat regulatory review as a pre-filing formality rather than a live execution risk are mispricing that risk.
The Anthropic situation is the second most important, and it is being misread in both directions. Some coverage is treating the reported investor pushback as evidence that the offering is in trouble. That is wrong. A nine-bank syndicate with five retail distribution participants, led by Goldman Sachs, is built precisely to absorb contested opinion on valuation. The pushback reported on November 5 is the process working. But it is equally wrong to treat the filing as evidence that the offering will price at the valuation investors have discussed. The reported $1.5 trillion figure is not a confirmed valuation, no price range has been filed, and a company with $17 billion of quarterly revenue and substantial disclosed compute commitments is exactly the kind of issuer where public-market investors will apply their own model before agreeing to a number. The honest reading is that the offering is progressing through normal institutional scrutiny, and that the next datapoint — the filing of a price range — will be more informative than anything reported this week.
Wonder’s confidential filing is a sign of preparation, not hesitation. A company built through the Grubhub and Blue Apron acquisitions, operating food halls, restaurant brands, delivery operations and technology, has a genuinely complicated reporting story. The confidential route allows it to work through segment reporting and purchase-accounting questions with the SEC before the numbers become public and become part of the valuation debate. The reported $9 billion pre-money valuation from its July round is a private-market number set under different conditions; the public market will price the business on its own terms, and the two figures should not be conflated.
The underwriting syndicates are the most under-read signal in this week’s filings. A nine-bank global syndicate plus five retail platforms for Anthropic; four specialist banks with one healthcare-focused lead manager for Rezera; four cross-border banks for OPay. These are not generic arrangements. Each describes the specific investor base the issuer needs, and each is a leading indicator of how the deal will be marketed. When a filing shows a syndicate that is broader than the deal size appears to require, it tells you something about the issuer’s expectations of demand. When it shows a narrow specialist syndicate, it tells you the deal is built for a defined buyer set.
The market is not one window; it is several. Rezera progressed through priced terms in the same week that OPay terminated and DT House withdrew. That divergence is not noise — it is what a sector-differentiated market looks like. Technology issuers are being held to a valuation discipline that reflects AI infrastructure economics. Biotech issuers are being supported by specialist investors who evaluate clinical risk on their own terms. Emerging-markets fintech issuers are absorbing regulatory risk that has become an execution variable. Treating these as the same market produces misleading conclusions about “the IPO environment.”
The caveat worth stating plainly: this edition rests on SEC filings, amended prospectuses and credible reporting. No price range has been set for Anthropic. No public terms have been disclosed for Wonder Group. OPay’s characterisation of the regulatory inquiry as immaterial is the company’s own framing, not an independently verified finding. The reported $1.5 trillion valuation and the reported $9 billion pre-money valuation are both expectations or private-market figures, not IPO valuations. The strategic read is defensible; the outcomes are not yet established. IPO Watch will follow up when price ranges are filed, roadshows are scheduled and listings — or further withdrawals — occur.
The CODEW Stat
One. Of the week’s major IPO developments, exactly one — Rezera — has a filed price range. Anthropic has an amended prospectus but no price range. Wonder has a confidential filing and no public terms. OPay priced and then terminated. DT House withdrew. Churchill Capital XIV filed an S-1 but has no offering terms beyond size. One issuer out of six is at the stage where a public investor can actually evaluate a price. That ratio is the most honest available measure of the IPO window: it is open, but it is not yet a market where many issuers are ready to be priced.
Sources & References
- Anthropic, PBC — public S-1 and amended prospectus (November 2, 2026), SEC EDGAR — sec.gov
- Reuters — prospective investors question Anthropic valuation expectations and roadshow timing (November 5, 2026) — reuters.com
- Wonder Group — confidential IPO filing announcement (November 5, 2026) — wonder.com
- OPay — IPO termination (November 2, 2026), including priced terms at $19 per share — opayweb.com
- Rezera Inc. — amended S-1 with proposed offering terms (November 5, 2026), SEC EDGAR — sec.gov
- Churchill Capital Corp XIV — S-1 filing (November 4, 2026), SEC EDGAR — sec.gov
- DT House Limited — IPO withdrawal (November 4, 2026), SEC EDGAR — sec.gov
- Guitar Group Ltd — F-1 filing (November 5, 2026), SEC EDGAR — sec.gov
- Kartoon Studios Acquisition Corp — SPAC registration filing (November 5, 2026), SEC EDGAR — sec.gov
- American Ventures Acquisition I — amended SPAC registration reducing offering to $75 million, SEC EDGAR — sec.gov
Issuer details, syndicates and offering terms are drawn from SEC filings and company announcements. Confidential filings, public filings, amendments, pricing, withdrawals, terminations and completed listings are distinguished throughout. The reported $1.5 trillion Anthropic valuation figure is an expectation attributed to sources and is not a confirmed offering valuation; no price range or share count has been filed. The $9 billion Wonder Group figure is a private funding-round pre-money valuation, not an IPO valuation. OPay’s characterisation of the regulatory inquiry as involving an immaterial jurisdiction is the company’s own framing. No future SPAC target is speculated about. This article does not provide investment advice.
Related Coverage
Reviewed by Erwin Castro
on
Friday, November 06, 2026
Rating:
No comments: